Sanofi and GlaxoSmithKline (GSK) said preliminary data from a phase 3 study showed that a booster dose of their experimental COVID-19 shot induces strong immunity but said they won’t release…

Did Gilead Sciences collude with other drug companies to delay its blockbuster HIV pills from reaching the end of their patents? Did the company offer sweet deals to a generic…

After a year of controversy for janus kinase (JAK) inhibitors, the FDA has now greenlighted two JAK inhibitors for inflammatory disease indications that had been delayed for months while the…

A global coalition of regulators has recommended permanent use of the remote inspections of drug manufacturing plants that regulatory bodies began to use during the COVID-19 pandemic. Source: Drug Industry…

President Biden’s pick to become FDA commissioner, Robert Califf, received bipartisan support yesterday during a Senate confirmation hearing in which he comfortably fielded questions from lawmakers. Source: Drug Industry Daily

Australian biotech firm CSL will purchase Swiss pharmaceutical company Vifor Pharma for $11.7 billion in a deal set to close in mid-2022, the companies announced. Source: Drug Industry Daily

In a bid to reduce healthcare costs, Oregon wants to create a closed formulary limiting the number of drugs in each class and potentially excluding drugs approved under the FDA’s…

Final data from the phase 2/3 study of Pfizer’s novel oral “at home” COVID-19 treatment, Paxlovid, was so strong, the candidate could be well-positioned to knock molnupiravir — which is…

The Senate Finance Committee has released amended Build Back Better Act text, which would exempt generics and biosimilars at risk of supply chain shortages from rebates drugmakers would have to…

Gilead and Bristol-Myers Squibb (BMS) are touting positive data from studies of their bespoke CAR-T cell treatments, each company hailing the results as a new treatment era for patients with…